Want to see LBRX full AI Analyst Report?
LB Pharmaceuticals, Inc. (LBRX) Stock Statistics & Valuation Metrics
Total Valuation
LB Pharmaceuticals, Inc. has a market cap or net worth of $1.28B. The enterprise value is $655.55M.
- Market Cap
- $1.28B
- Enterprise Value
- $655.55M
Share Statistics
LB Pharmaceuticals, Inc. has 32,259,174 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 32,259,174
- Owned by Insiders
- 14.77%
- Owned by Institutions
- 21.52%
Financial Efficiency
LB Pharmaceuticals, Inc.’s return on equity (ROE) is -0.08 and return on invested capital (ROIC) is -9.93%.
- Return on Equity (ROE)
- -0.08
- Return on Assets (ROA)
- -0.08
- Return on Invested Capital (ROIC)
- -9.93%
- Return on Capital Employed (ROCE)
- -0.10
- Revenue Per Employee
- 0
- Profits Per Employee
- -514.39K
- Employee Count
- 49
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of LB Pharmaceuticals, Inc. is -13.37. LB Pharmaceuticals, Inc.’s PEG ratio is -0.08.
- PE Ratio
- -13.37
- PS Ratio
- 0.00
- PB Ratio
- 3.60
- Price to FCF
- -15.46
- Price to Operating Cash Flow
- -14.52
- PEG Ratio
- -0.08
Income Statement
In the last 12 months, LB Pharmaceuticals, Inc. had revenue of 0 and earned -25.20M in profits. Earnings per share was -1.00.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -30.40M
- Pretax Income
- -25.20M
- Net Income
- -25.20M
- EBITDA
- -24.88M
- Earnings Per Share (EPS)
- -1.00
Cash Flow
In the last 12 months, operating cash flow was -82.39M and capital expenditures -435,000, giving a free cash flow of -82.83M billion.
- Operating Cash Flow
- -82.39M
- Free Cash Flow
- -82.83M
- Free Cash Flow per Share
- -2.75
Dividends & Yields
LB Pharmaceuticals, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -6.47%
- Earnings Yield
- -7.16%
Stock Price Statistics
- Beta
- 1.54
- 52-Week Price Change
- 143.86%
- 50-Day Moving Average
- 41.41
- 200-Day Moving Average
- 32.81
- Relative Strength Index (RSI)
- 52.93
- Average Volume (3m)
- 368.27K
Important Dates
LB Pharmaceuticals, Inc. upcoming earnings date is Nov 05, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 11, 2026
- Next Earnings Date
- Nov 05, 2026
- Ex-Dividend Date
- ―
Financial Position
LB Pharmaceuticals, Inc. as a current ratio of 41.44, with Debt / Equity ratio of 1.18%
- Current Ratio
- 41.44
- Quick Ratio
- 41.44
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 9.91
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, LB Pharmaceuticals, Inc. has paid 1,000 in taxes.
- Income Tax
- 1,000
- Effective Tax Rate
- -0.00
Enterprise Valuation
LB Pharmaceuticals, Inc. EV to EBITDA ratio is -11.44, with an EV/FCF ratio of -12.11.
- EV to Sales
- 0.00
- EV to EBITDA
- -11.44
- EV to Free Cash Flow
- -12.11
- EV to Operating Cash Flow
- -12.17
Balance Sheet
LB Pharmaceuticals, Inc. has $327.79M in cash and marketable securities with $5.22M in debt, giving a net cash position of $322.57M billion.
- Cash & Marketable Securities
- $327.79M
- Total Debt
- $5.22M
- Net Cash
- $322.57M
- Net Cash Per Share
- $10.00
- Tangible Book Value Per Share
- $11.03
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for LB Pharmaceuticals, Inc. is $60.70, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $60.70
- Price Target Upside
- 52.90% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 10
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -132.05%
Scores
- Smart Score
- 10
- AI Score
- 48
